Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study

Jieping Yang¹, Paula H. Summanen², Susanne M. Henning¹, Mark Hsu¹, Heiman Lam¹, Jianjun Huang¹, Chi-Hong Tseng³, Scot E. Dowd⁴, Sydney M. Finegold⁵, David Heber¹ and Zhaoping Li¹*

¹Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA,
²Infectious Diseases Section, VA West Los Angeles Medical Center, Los Angeles, CA, USA,
³Department of Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA,
⁴MR DNA Molecular Research LP, Shallowwater, TX, USA,
⁵Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA

Background: It has been suggested that gut microbiota is altered in Type 2 Diabetes Mellitus (T2DM) patients.

Objective: This study was to evaluate the effect of the prebiotic xylooligosaccharide (XOS) on the gut microbiota in both healthy and prediabetic (Pre-DM) subjects, as well as impaired glucose tolerance (IGT) in Pre-DM.

Subjects/Methods: Pre-DM (n = 13) or healthy (n = 16) subjects were randomized to receive 2 g/day XOS or placebo for 8-weeks. In Pre-DM subjects, body composition and oral glucose tolerance test (OGTT) was done at baseline and week 8. Stool from Pre-DM and healthy subjects at baseline and week 8 was analyzed for gut microbiota characterization using Illumina MiSeq sequencing.

Results: We identified 40 Pre-DM associated bacterial taxa. Among them, the abundance of the genera Enterorhabdus, Howardella, and Slackia was higher in Pre-DM. XOS significantly decreased or reversed the increase in abundance of Howardella, Enterorhabdus, and Slackia observed in healthy or Pre-DM subjects. Abundance of the species Blautia hydrogenotrophica was lower in pre-DM subjects, while XOS increased its abundance. In Pre-DM, XOS showed a tendency to reduce OGTT 2-h insulin levels (P = 0.13), but had no effect on body composition, HOMA-IR, serum glucose, triglyceride, satiety hormones, and TNFα.

Conclusion: This is the first clinical observation of modifications of the gut microbiota by XOS in both healthy and Pre-DM subjects in a pilot study. Prebiotic XOS may be beneficial in reversing changes in the gut microbiota during the development of diabetes.

Clinical trial registration: NCT01944904 (https://clinicaltrials.gov/ct2/show/NCT01944904).

Keywords: xylooligosaccharide, prediabetic, diabetes, gut, microbiota

Abbreviations: XOS, xylooligosaccharide; Pre-DM, prediabetic; BMI, body mass index; T2DM, Type 2 Diabetes Mellitus; FOS, fructooligosaccharides; GOS, galactooligosaccharides; OGTT, oral glucose tolerance test OGTT.
Introduction

Increasing evidence indicates that changes in gut microbiota composition might contribute to the development of metabolic disorders such as obesity and T2DM (Qin et al., 2012). Several mechanisms have been proposed regarding how gut bacteria could facilitate the pathogenesis of T2DM (Shen et al., 2013). Studies suggest that gut bacteria influence whole-body metabolism through regulation of the host's immune response, energy extraction and utilization, intestinal glucose absorption, and lipid metabolism (Musso et al., 2011). The central feature of obesity and T2DM is insulin resistance, potentially caused by low-grade inflammation resulting from nutrient excess and leading to endoplasmic reticulum (ER) stress. More and more research has shown that gut microbiota is another important factor for this low-grade inflammation (Chassaing and Gewirtz, 2014). The Bacteroidetes/Firmicutes ratio is associated with increased plasma glucose concentrations and a decrease in butyrate-producing bacteria in T2DM patients (Larsen et al., 2010; Shen et al., 2013). Recent studies in mice have demonstrated that an increase in the abundance of Bifidobacteria and Akkermansia muciniphila attenuated high fat diet-induced metabolic complications (Everard et al., 2013).

Pre-DM refers to the intermediate stage between normoglycemia and overt diabetes mellitus. Pre-DM is characterized by glucose dysregulation and a higher risk of developing T2DM and other associated complications (Portero McLellan et al., 2014). However, not all individuals with Pre-DM progress to overt T2DM. With changes in lifestyle and diet, the progression of Pre-DM to T2DM can be prevented or delayed (Portero McLellan et al., 2014). Given the significant involvement of certain gut bacteria in host metabolism (Shen et al., 2013), therapeutic manipulation of the gut microbiota has been proposed for both individuals with T2DM and in those at risk of developing the condition.

Prebiotics are highly effective and important for many applications in medicine. They are not digestible and do not contribute to human nourishment, but rather exert a profound effect on the human gut microbiota (International Scientific Association for Probiotics and Prebiotics, 2004). Prebiotic-induced modulation of gut microbiota has been developed and widely used (Everard et al., 2011). The principal effect of prebiotics on the human gut microbiota is to stimulate the growth of the Bifidobacterium and Lactobacillus genera (Marotti et al., 2012). Prebiotic treatment is known to modulate host gene expression and metabolism as well (Everard et al., 2011). Dietary intervention using prebiotic inulin or oligofructose (FOS) alters the gut microflora composition by promoting the growth of beneficial bacteria such as Bifidobacterium, Lactobacillus, and A. muciniphila (Rossi et al., 2005; Choi and Shin, 2006). However, the mechanisms associating prebiotics and its beneficial effects have yet to be fully understood. Further studies are needed to examine the precise physiological roles of prebiotics on human bowel flora and in host immune function.

Xylooligosaccharide (XOS) is a recent prebiotic that can be incorporated into many food products (Aachary and Prapulla, 2011). Our lab previously reported that XOS, at the dose of 2.8 g/day, was well tolerated, and modified the gut bacterial composition in healthy people (Finegold et al., 2014). A consideration of the gut microbiota in the context of health benefits of XOS in Pre-DM is especially relevant since recent research has indicated a critical role of gut microbiota in the development of T2DM (Qin et al., 2012). The present study was designed to determine the effect of XOS supplementation on the gut microbiota in healthy and pre-DM individuals. Since the ultimate objective of this research is to explore the potential effects of XOS in the prevention of progression of Pre-DM to T2DM, we also evaluated the effects of XOS in the management of IGT, body composition, and inflammatory marker in Pre-DM subjects.

Materials and Methods

Subjects

This was a double-blind, randomized, placebo-controlled study with 34 subjects who were recruited based on inclusion and exclusion criteria. The study population consisted of 16 healthy subjects (placebo: n = 9; XOS: n = 7) and 13 Pre-DM subjects (placebo: n = 6; XOS: n = 7).

Ethics

The study was carried out in accordance with the guidelines of the Office for Protection of Research Subjects of the University of California, Los Angeles and the Institutional Review Board of the VA Greater LA Health Center. All subjects provided written informed consent before the study began.

Study Design

The enrollment criteria for healthy participants was fasting plasma glucose of 65–100 mg/dl. Participants in the Pre-DM study were selected based on the American Diabetes Association criteria for impaired fasting glucose (fasting plasma glucose of 100–125 mg/dl) and/or HgbA1c (5.7–6.4%) (American Diabetes Association, 2014). Over the span of 8 weeks, both healthy and Pre-DM subjects were randomly assigned to take daily a capsule supplement containing either 2 g XOS (2.8 grams of 70% XOS) or placebo. The XOS and placebo were provided by Life Bridge International (Riverside, CA). The XOS was manufactured by Shandong Longlive Bio-Technology Co., Ltd., China. The placebo capsules contained maltodextrin. The study consisted of three phases: a 2-week run-in phase, and an 8-week intervention phase.

Stool Collection

A total of two stools were collected from each subject: at baseline and week 8 of the intervention periods. Each time the entire stool specimen was obtained. The specimen was placed in a large, zip-lock freezer bag and all air was pushed out of the bag as the zip lock was closed. The specimen was delivered on ice to the UCLA Center for Human Nutrition within 24 h of collection where it was immediately stored at −20°C.

Miseq Sequencing

DNA from stool was extracted using a commercial extraction system (QIAamp Stool DNA Extraction Kit, Qiagen, Valencia,
The quality of the DNA samples was confirmed using a Bio-Rad Experion system (Bio-Rad Laboratories, CA, USA). The 16S rRNA gene V4 variable region PCR primers 515/806 with barcode on the forward primer were used in a 30 cycle PCR using the HotStarTaq Plus Master Mix Kit (Qiagen, USA) under the following conditions: 94°C for 3 min, followed by 28 cycles of 94°C for 30 s, 53°C for 40 s and 72°C for 1 min, after which a final elongation step at 72°C for 5 min was performed. After amplification, PCR products are checked in 2% agarose gel to determine the success of amplification and the relative intensity of bands. Sequencing was performed at MR DNA (www.mrdnalab.com, Shallowater, TX, USA) on a MiSeq following the manufacturer's guidelines. Sequence data were processed using a proprietary analysis pipeline (MR DNA, Shallowater, TX, USA). Operational taxonomic units (OTUs) were defined by clustering at 3% divergence (97% similarity). Final OTUs were taxonomically classified using BLASTn against a curated GreenGenes database (DeSantis et al., 2006).

Body Composition
Body composition was measured using the Tanita-BC418 bioelectrical impedance analyzer (Tanita Corp., Japan).

Glucose Tolerance Test
On the test days at baseline and week 8, Pre-DM subjects remained in a fasting state for 2.5 h prior to the beginning of OGTT. The 75 g glucose cola was administrated immediately after the basal blood draw at 0 min. Subsequent blood samples were taken 30, 60, and 120 min afterwards. Serum samples were kept at −80°C. The insulin resistance index assessed by the homeostasis model (HOMA-IR) was calculated as follows (Allard et al., 2003): (fasting blood glucose [mmol/l] × fasting plasma insulin [μU/ml])/22.5.

Blood Biochemical Analysis
Blood samples were collected and coded to protect patient confidentiality. Lipids, insulin, glucose, and satiety hormones were measured. Serum triglycerides were determined using an enzymatic method (Pointe Scientific, MI). Serum glucose was determined using Glucose Assay kit (Cayman Chemical Company, MI). Serum insulin, active GLP-1, leptin, pancreatic polypeptides (PP) and TNFα were determined using the MILLIPLEX map kit (EMD Millipore, Billerica, MA) and data were captured and processed using Luminext 200 with xPonent software.

TABLE 1 | Baseline characteristics of the study participants.

|                      | Healthy placebo (n = 9) | Healthy XOS (n = 7) | Pre-DM placebo (n = 6) | Pre-DM XOS (n = 7) |
|----------------------|-------------------------|---------------------|------------------------|-------------------|
| Age, year            | 31.9 ± 6.9              | 31.7 ± 9.3          | 44.8 ± 11.2            | 55.0 ± 6.2        |
| Weight, kg           | 65.4 ± 14.0             | 69.9 ± 13.0         | 94.9 ± 15.9            | 97.4 ± 22.7       |
| BMI, kg/m²           | 23.4 ± 3.2              | 25.6 ± 3.2          | 33.6 ± 7.2             | 32.2 ± 4.2        |

Values are presented as mean ± standard deviation (SD). For all characteristics, there were no significant differences between the placebo and XOS groups (all P > 0.05, based on independent sample t-tests). BMI, body mass index.
Effects of XOS Supplementation on the Gut Microbiota in Healthy and Pre-DM Subjects

The overall changes of bacterial composition with 8-week XOS intervention were assessed at the phylum and genus levels (Figures 2, 3). Significant XOS-induced changes were found for 1 phyla, 3 classes, 25 genera, and 25 species in healthy subjects (Figure 2 and Supplementary Table 2), and 3 classes, 17 genera, and 17 species in Pre-DM subjects (Figure 3 and Supplementary Table 3). The mean abundance of indicated phyla of healthy subjects in placebo and XOS groups at baseline and week 8 are displayed in Figure 2A. The phylum Firmicutes showed a 20% increase in abundance over 8 weeks in placebo groups of healthy subjects, while XOS intervention significantly reversed this increase ($P \leq 0.05$) (Figure 2A). The mean abundance of Verrucomicrobia increased in XOS groups of healthy subjects as well. Among genera with an average abundance $>1\%$ in at least one group, six were significantly regulated by XOS. An increase of infectious disease related Streptococcus and Subdoligranulum in placebo groups was largely inhibited by XOS in healthy subjects (Figure 2B). The 8-week XOS intervention did not induce significant changes of gut microbiota at the phylum level in Pre-DM subjects (Figure 3A). At the genus level, Blautia, Anaerotruncus, Dialister, and Oscillospira were four abundant genera identified with significant XOS-induced changes in Pre-DM subjects. XOS diminished or reversed the magnitude of population decline in all four genera (Figure 3B).
Xylooligosaccharide and Microbiota

Effects of XOS supplementation on gut microbiota in healthy subjects (n = 16). (A) Pie charts display the mean abundance of indicated phyla of healthy subjects receiving placebo (n = 9) and XOS (n = 7) at baseline and week 8. (B) Bar graph of genera shows significant difference in abundance between placebo and XOS groups. Values are presented as mean ± standard error (SE) *P ≤ 0.05.

XOS Supplementation Reversed Gut Bacterial Alterations Associated with Pre-DM

Of the 40 Pre-DM associated bacterial taxa (Supplementary Table 1) identified in this study, the abundances of the *Enterorhabdus*, *Howardella*, and *Slackia* genera were elevated in Pre-DM. The 8-week XOS intervention significantly diminished or reversed the abundance increase of *Howardella* and *Slackia* observed in the placebo group of healthy subjects, as well as *Enterorhabdus* in Pre-DM subjects (Figures 4A–C). *B. hydrogenotrophica* was less abundant in Pre-DM subjects (Supplementary Table 1), but XOS intervention significantly reversed the decrease in *B. hydrogenotrophica* abundance observed in the placebo group of Pre-DM subjects (*P ≤ 0.05*) (Figure 4D).

Effects of XOS on Body Composition, Metabolic, and Immunological Markers in Pre-DM Subjects

In Pre-DM subjects, body composition, blood tests, and oral glucose tolerance tests (OGTT) were done at baseline and after 8 weeks of XOS intervention. Body weight and indexes of overall adiposity such as BMI, % fat, and % trunk fat were not changed by 8-week XOS intervention (Figure 5). Despite significant inter-individual variations in insulin responses...
among Pre-DM subjects, OGTT 2-h insulin response showed a tendency to decrease with XOS intervention in Pre-DM ($P = 0.13$) (Figure 6A). No significant XOS-related differences were observed in serum glucose, HOMA-IR, active GLP-1, triglycerides, leptin, PP, or the inflammatory marker TNFα (Figures 6B–H).

**Discussion**

Emerging evidence suggests that metabolic disorders including T2DM are associated with a pro-inflammatory state secondary to dysbiosis of gut bacterial flora (Larsen et al., 2010; Esteve et al., 2011; Musso et al., 2011). In addition, literature has documented the translocation of gut bacteria to blood and tissues in T2DM, and probiotic *Bifidobacterium* treatment prevents bacterial translocation and protects against T2DM (Cani et al., 2007; Amar et al., 2011). Together, these findings suggest that gut bacteria are an important modifier of T2DM.

The effects of oligosaccharides including XOS, FOS, and galactooligosaccharides (GOS) in the treatment of T2DM have gained interest. However, studies have shown inconsistent results. In T2DM patients, Yamashita et al. demonstrated that...
FOS at a dose of 8 g per day for 14 days resulted in a reduction of serum glucose, while Alles et al. showed that daily consumption of FOS at 15 g for 20 days had no effect on serum glucose level (Yamashita et al., 1984; Alles et al., 1999). Chan et al. showed that 4 g per day of XOS for 8 weeks was effective in reducing blood glucose and lipids in Taiwan T2DM patients (Sheu et al., 2008), and for 21 days benefited intestinal health and increased of *Bifidobacteria* in elderly subjects (Chung et al., 2007). Another study reported that both XOS and FOS dietary intervention reduced hyperglycaemia in diabetic rats (Gobinath et al., 2010). In addition, we found that 2 g per day of XOS for 8 weeks increased the *Bifidobacteria* abundance in healthy Americans without any gastrointestinal side effects (Finegold et al., 2014). Overall, a significant number of studies have shown oligosaccharides to be an effective option for lowering blood sugar in T2DM as well as improving intestinal health.
In the present study, both healthy and Pre-DM subjects were given 2 g per day of XOS for 8 weeks. Miseq sequencing was used to evaluate the potential of XOS in preventing the dysbiosis of gut microbiota during the development of T2DM. We found that XOS had a clear impact on gut microbiota in both healthy and Pre-DM groups, and resulted in dramatic shifts of several bacterial taxa associated with Pre-DM. Among them, Dialister spp. and Slackia are pro-inflammatory (Rocas and Siqueira, 2006; Kim et al., 2010), and were greatly reduced by XOS. Additionally, T2DM associated lactic acid bacteria Enterococcus, Streptococcus, and Lactobacillus (Remely et al., 2013) were also greatly reduced by XOS. The inhibitory effect of XOS on other opportunistic pathogens, such as Clostridia, Streptococaceae, and Subdoligranulum, further supports that XOS can potentially promote an optimal gut microbiota profile, and consequently reduce the risk of T2DM.

Miseq sequencing data also revealed that gut microbial composition of healthy subjects at different taxonomic levels was different from Pre-DM subjects. Some of our findings are consistent with previous T2DM studies of gut microflora...
Tims et al., and patients of Crohn’s, were more abundant in Pre-DM. Since we enrolled pre-DM (Hooda et al., 2012) and much lower than T2DM (range from 87 to 112 pg/ml) (Goyal et al., 2012). Eight weeks Dietary whole grain intervention (Goyal et al., 2012). Therefore, more studies are needed to (4.91 ± 1.85 pg/ml) of Pre-DM subjects in our study are normal, slightly lower than the reported TNFα (~15–20 pg/ml) of eastern Indian Pre-DM population (Dutta et al., 2013) and much lower than T2DM (range from 87 to 112 pg/ml) (Goyal et al., 2012). Since we enrolled pre-DM subjects with impaired glucose tolerance (IGT) and without any other medical conditions we possibly did not observe elevated TNFα level. Pre-DM is a dynamic intermediate stage in the progression to T2DM, therefore it is very likely, subjects that met the selection criteria for Pre-DM are at different stages even though they are all classified as Pre-DM. Besides, studies also suggest a connection between TNFα gene polymorphism, its blood levels and the tendency to progression from Pre-DM to T2DM (Dutta et al., 2013). Therefore, more studies are needed to improve our understanding of the relationship between TNFα, Pre-DM staging, and T2DM progression. Our results do not agree with Chan et al. study in T2DM. However, this discrepancy could be explained by difference in XOS dose, study population and disease stages. It is possible that 2 g per day of XOS may have been too low to induce a difference in glucose tolerance. However, we observed a trend of increased insulin sensitivity by lowering OGTT 2-h insulin response at this dosage. Pre-DM is a strong risk factor for the development of T2DM, and the regulation of glucose metabolism and insulin sensitivity could be really dynamic during this stage. We think future clinical study with large sample size will be needed to confirm the benefits of XOS in Pre-DM.

In conclusion, XOS significantly modified gut microbiota in both healthy and Pre-DM subjects, and resulted in dramatic shifts of 4 bacterial taxa associated with Pre-DM. Future studies with larger sample size are needed to study the metabolic impact of XOS and understand the connection between XOS-mediated gut microbiota changes and the pathogenesis of T2DM.

### Source of Support
Supported by departmental funds from the Center for Human Nutrition, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.

### Acknowledgments
ZL and DH designed research and had primary responsibility for final content. SH, JY, MH, HM, JH, PS, and G. Thames conducted research. SF, CT, and JY analyzed the data. JY wrote paper.

### Supplementary Material
The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fphys.2015.00216
Gobinath, D., Madhu, A. N., Prashant, G., Srinivasan, K., and Prapulla, S. G. (2010). Beneficial effect of xylo-oligosaccharides and fructo-oligosaccharides in streptozotocin-induced diabetic rats. Br. J. Nutr. 104, 40–47. doi: 10.1017/S0007114510000243

Goyal, R., Faizy, A. F., Siddiqui, S. S., and Singhai, M. (2012). Evaluation of TSN-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. N. Am. J. Med. Sci. 4, 180–184. doi: 10.4103/1947-2714.94944

Hooda, S., Boler, B. M. V., Serao, M. C. R., Brulc, J. M., Staeger, M. A., Boileau, T. W., et al. (2012). 454 pyrosequencing reveals a shift in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber. J. Nutr. 142, 1259–1265. doi: 10.3945/jn.112.158766

International Scientific Association for Probiotics and Prebiotics. (2004). Probiotics, prebiotics, and new foods. Proceedings of the 2nd annual meeting. Rome, Italy, September 7–9, 2003. J. Clin. Gastroenterol. 38(Suppl.), S60–S129

Joussens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., et al. (2011). Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60, 631–637. doi: 10.1136/gut.2010.232263

Kang, D. W., Park, J. G., Ilhan, Z. E., Wallstrom, G., Laber, J., Adams, J. B., et al. (2013). Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS ONE 8:e68322. doi: 10.1371/journal.pone.0068322

Kim, K. S., Rowlinson, M. C., Bennion, R., Liu, C., Talan, D., Summanen, P., et al. (2010). Characterization of Slackia exigua isolated from human wound infections, including abscesses of intestinal origin. J. Clin. Microbiol. 48, 1070–1075. doi: 10.1128/JCM.01576-09

Larsen, N., Vogensen, F. K., van den Berg, F. W., Nielsen, D. S., Andreason, A. S., Pedersen, B. K., et al. (2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5:e90085. doi: 10.1371/journal.pone.0090085

Marotti, I., Bregola, V., Aloisio, I., Di Gioia, D., Bossi, S., Di Silvelsto, R., et al. (2012). Prebiotic effect of soluble fibres from modern and old durum-type wheat varieties on Lactobacillus and Bifidobacterium strains. J. Sci. Food Agric. 92, 2313–2340. doi: 10.1002/jsfa.5597

Martínez, I., Lattimer, J. M., Hubach, K. L., Case, J. A., Yang, J. Y., Weber, C. G., et al. (2013). Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 7, 269–280. doi: 10.1038/ismej.2012.104

Musso, G., Gambino, R., and Cassader, M. (2011). Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu. Rev. Med. 62, 361–80. doi: 10.1146/annurev-med-012510-175505

Plisetskij, J. L., Deenonrop, R., Mulvanna, J. P., Krause, L., Sripa, B., Betheny, J. M., et al. (2013). Infection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome. Faseb J. 27, 4572–84. doi: 10.1096/fj.13-232751

Porter McCellan, K. C., Wyne, K., Villagomez, E. T., and Hsueh, W. A. (2014). Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther. Clin. Risk Manag. 10, 173–188. doi: 10.2147/TCRM.S9564

Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., et al. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60. doi: 10.1038/nature11450

Remely, M., Dворзак, S., Hippke, B., Zwielenker, J., Aumüller, E., Brath, H., et al. (2013). Abundance and diversity of microbiota in type 2 diabetes and obesity. J. Diab. Metab. 2:453. doi: 10.4172/2155-6156.1000253

Rocasco, L. N., and Siqueira, J. F. R. (2006). Characterization of Dialister species in infected root canals. J. Endod. 32, 1057–1061. doi: 10.1016/j.joen.2006.04.010

Rossi, M., Corradini, C., Amaretti, A., Nicolini, M., Pompei, A., Zannoni, S., et al. (2005). Fermentation of fructooligosaccharides and inulin by bifidobacteria: a comparative study of pure and fecal cultures. Appl. Environ. Microbiol. 71, 6150–6158. doi: 10.1128/AEM.71.10.6150-6158.2005

Shen, J., Ohin, M. S., and Zhao, L. (2013). The gut microbiota, obesity and insulin resistance. Mol. Aspects Med. 34, 39–58. doi: 10.1016/j.mam.2012.11.001

Shew, W. H., Lee, I. T., Chen, W., and Chan, Y. C. (2008). Effects of xylooligosaccharides in type 2 diabetes mellitus. J. Nutr. Sci. Vitaminol. (Tokyo) 54, 396–401. doi: 10.3177/jnsv.54.396
Tims, S., Derom, C., Jonkers, D. M., Vliezinc, R., Saris, W. H., Kleerebezem, M., et al. (2013). Microbiota conservation and BMI signatures in adult monozygotic twins. *ISME J.* 7, 707–717. doi: 10.1038/ismej.2012.146

Vartoukian, S. R., Palmer, R. M., and Wade, W. G. (2007). The division "Synergistes". *Anaerobe* 13, 99–106. doi: 10.1016/j.anaerobe.2007.05.004

Yamashita, K., Kawai, K., and Itakura, M. (1984). Effects of fructo-oligosaccharides on blood-glucose and serum-lipids in diabetic subjects. *Nutr. Res.* 4, 961–966. doi: 10.1016/S0271-5317(84)80075-5

Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., et al. (2013). Human gut microbiota changes reveal the progression of glucose intolerance. *PLoS ONE* 8:e71108. doi: 10.1371/journal.pone.0071108

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Yang, Summanen, Henning, Hou, Lam, Huang, Tseng, Dowd, Finegold, Heber and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.